Drugs / QLM1016
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06799559 | May 2025 → Jul 2026 overdue | schizophrenia | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLM1016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06799559 ↗ |
| Route | Oral | “administered orally once daily” NCT06799559 ↗ |